| Course | NU 670 Advanced Psychopharmacology and Health Promotion |
|---|---|
| Unit | Unit 6 |
| Paper type | Special population pharmacology brief |
| Length | About 1,070 words, 6 pages |
| Format | APA 7 student paper |
| School | Herzing University |
| Program | MSN Psychiatric Mental Health Nurse Practitioner |
| Updated | October 2026 |
Free sample paper for NU 670 Unit 6
Lamotrigine for Bipolar Disorder During Pregnancy and After Delivery: Which Step of Handling Shifts, How Far, and What to Do
Student Name
Department of Nursing, Herzing University
NU 670: Advanced Psychopharmacology and Health Promotion
Instructor Name
February 25, 2026
Lamotrigine for Bipolar Disorder During Pregnancy and After Delivery: Which Step of Handling Shifts, How Far, and What to Do
The Population and the Question
The population is women with bipolar disorder who are maintained on lamotrigine and who become pregnant or plan pregnancy. Lamotrigine is often preferred for maintenance in women of reproductive age because, among mood stabilizers, it carries a comparatively favorable profile for fetal development; data from a large pregnancy registry found that the risk of major malformations with lamotrigine monotherapy was not markedly higher than in unexposed pregnancies, in contrast to valproate (Hernández-Díaz et al., 2012). The question for this brief is not whether to use lamotrigine in pregnancy, a decision made with each woman, but how pregnancy changes what the drug does once the decision is made.
Which Step of Handling Shifts
Absorption, distribution, and binding change only modestly in pregnancy for lamotrigine. The step that shifts substantially is clearance. Lamotrigine is cleared mainly by glucuronidation in the liver, through the enzyme UGT1A4, and the high estrogen levels of pregnancy induce this pathway. Renal blood flow also rises. The result is that lamotrigine is removed faster, and at an unchanged dose, blood levels fall.
How Far It Shifts
The change is large and progressive. In a prospective study of pregnant women taking lamotrigine for epilepsy, clearance increased steadily through pregnancy, reaching its highest levels in the third trimester, with wide variation between women; seizures became more frequent when lamotrigine levels fell well below the woman's pre-pregnancy level (Pennell et al., 2008). A study of pregnant women with bipolar disorder found a similar rise in clearance through pregnancy, and reported that declining levels were associated with worsening depressive symptoms (Clark et al., 2013). The size of the increase varies considerably from woman to woman, which is why the literature points toward monitoring each woman's levels rather than applying a fixed dose increase.
What Happens After Delivery
After delivery, estrogen levels fall abruptly and lamotrigine clearance returns toward its pre-pregnancy level within a few weeks. If the dose was increased during pregnancy and not reduced after delivery, blood levels can rise quickly, causing dizziness, double vision, unsteadiness, and sedation, which are dangerous for a woman caring for a newborn. At the same time, the postpartum period is one of the highest-risk periods for relapse of bipolar disorder, so an overly aggressive reduction is also risky. Both errors are common enough that the postpartum plan must be written before delivery, not after.
What to Do
Before pregnancy, or as early as possible in it: measure a lamotrigine level while the woman is well, to serve as her individual target. Confirm that the dose was established without valproate, since valproate doubles lamotrigine levels and its presence changes every calculation.
During pregnancy: check levels every four weeks, or more often in the third trimester, and at any sign of mood worsening. Increase the dose in steps to keep the level near the pre-pregnancy target, rather than by a fixed percentage. Assess mood at every visit with a validated scale, since symptom change may precede a measured fall in level.
Before delivery: write a postpartum taper plan with the obstetric team, specifying dose reductions over the first two to three weeks toward the pre-pregnancy dose, and a level check at about two weeks postpartum.
After delivery: follow the plan, ask about dizziness, double vision, and sedation, and assess mood closely, since both toxicity and relapse are possible in the same weeks. Breastfeeding is generally compatible with lamotrigine, though infants should be watched for sedation or rash, and the pediatric clinician should be informed.
A Worked Example
Ms. T., a composite 29-year-old woman with bipolar I disorder, has been well for three years on lamotrigine 200 mg daily, with no other mood stabilizer. Her pre-pregnancy lamotrigine level, drawn when she began trying to conceive, was 4.0 mcg/mL, which becomes her individual target. At 20 weeks, her level had fallen to 2.6 mcg/mL, about 65% of target, and she reported poorer sleep and lower mood for two weeks; the dose was raised to 250 mg. At 28 weeks, the level was 2.4 mcg/mL on the higher dose, 60% of target, as clearance continued to rise, and the dose was raised to 300 mg. At 34 weeks, the level was 3.6 mcg/mL, 90% of target, and her mood was stable.
The postpartum plan, written at 34 weeks, reduced the dose to 250 mg on the third day after delivery and to 200 mg on the tenth day, with a level at two weeks. Her two-week level was 4.3 mcg/mL on 200 mg, close to her pre-pregnancy value, and she reported no dizziness. Her mood was checked weekly for the first six weeks by phone and at a visit. Without the plan, a woman in her position would have stayed on 300 mg after delivery while her clearance fell back, and her level could have risen well above her usual target within days.
What the Woman Is Told
Before pregnancy, she is told that her body will clear the medicine faster as pregnancy advances, that her dose will probably need to go up, that blood tests will guide the changes, and that after the birth the dose will come down again on a schedule already agreed. She is asked to report low mood, poor sleep, or racing thoughts at any point, and dizziness or double vision after delivery, rather than waiting for the next appointment.
Special Cautions
Estrogen-containing contraceptives induce the same pathway, so a woman who stops or starts them after delivery will see levels change again. Any rash in the first weeks after a dose increase should be evaluated, since the risk of serious rash with lamotrigine is highest with rapid dose escalation, although it is uncommon in someone already established on the drug. And the full treatment plan, including folic acid and fetal monitoring, is shared with the obstetric clinician, since the psychiatric prescriber alone cannot manage a pregnancy (Stahl, 2021).
Summary
Pregnancy shifts one step of lamotrigine handling, clearance, upward by an amount that differs widely between women and peaks late in pregnancy; delivery reverses it within weeks. The handling that follows is individual: a pre-pregnancy level as the target, regular levels during pregnancy, and a written postpartum reduction plan. The aim throughout is to keep the woman at the level that kept her well before pregnancy, not merely at a dose.
References
Clark, C. T., Klein, A. M., Perel, J. M., Helsel, J., & Wisner, K. L. (2013). Lamotrigine dosing for pregnant patients with bipolar disorder. American Journal of Psychiatry, 170(11), 1240-1247. https://doi.org/10.1176/appi.ajp.2013.13010006
Hernández-Díaz, S., Smith, C. R., Shen, A., Mittendorf, R., Hauser, W. A., Yerby, M., & Holmes, L. B. (2012). Comparative safety of antiepileptic drugs during pregnancy. Neurology, 78(21), 1692-1699. https://doi.org/10.1212/WNL.0b013e3182574f39
Pennell, P. B., Peng, L., Newport, D. J., Ritchie, J. C., Koganti, A., Holley, D. K., Newman, M., & Stowe, Z. N. (2008). Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency. Neurology, 70(22 Pt. 2), 2130-2136. https://doi.org/10.1212/01.wnl.0000289511.20864.2a
Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.
Reading the NU 670 Unit 6 instructions
Unit 6 asks you to analyze how a special population changes the handling of a psychotropic medication. Expect to define the population and agent, identify which pharmacokinetic step shifts, describe how far and when, explain what happens when the condition ends and recommend actions. Many versions focus on pregnancy, older adults, children or renal and hepatic impairment. Check which populations your section expects. Separate absorption, distribution, metabolism and elimination so the shifting step is clear. Cite prospective studies where available. A worked example with doses and levels makes the recommendations concrete. Avoid giving direct clinical advice to a real person; frame the analysis around a composite patient and the evidence behind each step of the plan.
How the NU 670 Unit 6 example is put together
The brief opens with the population and the question. The next section walks through each pharmacokinetic step and shows that clearance is the one that changes substantially. The extent section quantifies the change with study data and notes how much it varies between women. The postpartum section explains the rapid return and its risk. The action section gives a sequence from before pregnancy through the weeks after delivery. The worked example applies the plan to a composite patient with doses and levels at each stage. The section on what the woman is told translates the plan into plain language. The cautions section covers contraceptives that use the same pathway. The summary restates the main finding in two sentences.
Reading the NU 670 Unit 6 rubric
Herzing's rubric for a special population brief typically covers the identification of the population and agent, analysis of pharmacokinetic changes, quantification, postpartum or recovery changes, recommendations, patient education and writing. The pharmacokinetic analysis is where graders look hardest, since the brief must name the step that shifts and explain why. Quantification points reward data from prospective studies. Recommendation criteria look for a monitoring and dosing plan tied to the evidence. Postpartum changes often earn their own credit. Patient education points go to plain explanations. Pennell's prospective study and Hernández-Díaz's registry analysis belong in the APA 7 references. A worked example with doses and levels at each stage is often what lifts the recommendations into the top band, because it shows the plan can actually be followed.
NU 670 Unit 6 help before you submit
Special population briefs in Unit 6 usually lose points by stating that doses change in pregnancy without identifying which step shifts. Another frequent problem is leaving out the postpartum period, when toxicity risk rises. Students often give a single dose adjustment instead of a monitoring plan. Variation between women is ignored. Contraceptive interactions are missed. Worked examples are absent, so recommendations stay abstract. Finally, keep the analysis general rather than advising a real patient, because graders expect a composite case and evidence-based reasoning, and a brief that reads like personal medical advice raises concerns. Monthly levels with a baseline taken while the woman is well give the plan a target, which a single dose increase cannot.
Get a NU 670 Unit 6 example written to your instructions
Send the Unit 6 instructions and the rubric from your NU 670 classroom, naming the population the brief should cover. We write a custom example with the group bounded first, all four handling steps given verdicts, evidence quality kept beside each claim, magnitudes cited, and consequences held at the level of measurement. First custom sample free, returned within 24 to 48 hours.
More NU 670 papers and PMHNP samples
- NU 670 Unit 1: Receptor activity brief
- NU 670 Unit 2: Clearance pathway table
- NU 670 Unit 3: Whole regimen interaction screen
- NU 670 Unit 4: Adverse effect derivation record
- NU 670 Unit 5: Metabolic monitoring protocol
- NU 670 Unit 7: Lifestyle and psychoeducation package
- NU 670 Unit 8: Regimen lifecycle dossier
- NU 673 Unit 6: Follow-up interval rationale
- NU 674 Unit 6: Shared decision making record
- NU 671 Unit 6: Rating instrument administration note
- NU 672 Unit 6: In-session ethical decision record
NU 670 Unit 6 questions, answered
Which populations does this unit usually mean?
Groups whose handling of an agent differs for a physiological reason: older adults, people with reduced hepatic or renal function, pregnancy and lactation, children and adolescents, and people carrying variants in a clearance enzyme. Your instructions may name one. Where the choice is open, pick the group you can source properly, because two of these are studied far more thinly than the rest.
How is pregnancy handled without giving advice?
By describing what is known and marking where the knowledge stops. State which handling steps alter across the stages, cite what the literature reports, and note that labeling and specialist resources are revised. Decisions about a pregnancy sit with the person, their prescriber and current authoritative sources, and a brief written for a course should say that plainly rather than implying otherwise.
Does the brief need pharmacogenomic detail?
Only where the instructions ask, or where the population is itself defined by a variant. When it appears, name the enzyme, the phenotype grouping, the direction exposure moves, and whether testing is routinely available. Keep the interpretation general, since what a phenotype means for one person, and whether testing is warranted at all, belongs with the prescriber and current guidance.
Where can I find a free NU 670 Unit 6 sample paper?
This page carries the complete NU 670 Unit 6 lamotrigine pregnancy brief at no cost, from the clearance shift to the worked example. A brief on another population, such as older adults or renal impairment, can be written on request.
Why do lamotrigine levels drop during pregnancy?
Rising estrogen increases glucuronidation, the main pathway that clears lamotrigine, so clearance climbs through pregnancy. After delivery it falls back within weeks, which is why this sample plans monthly levels and a postpartum dose reduction.